Neurocrine Biosciences Remainder of fiscal 2026 increased by 233.3% to $3.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.4%, from $2.60M to $3.00M.
other_lessor_operating_lease_payments_to_be_received_rem_517df6| Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $400.00K | $1.30M | $1.00M | $800.00K | $2.60M | $1.70M | $900.00K | $3.00M |
| QoQ Change | — | +225.0% | -23.1% | -20.0% | +225.0% | -34.6% | -47.1% | +233.3% |
| YoY Change | — | — | — | +100.0% | +100.0% | +70.0% | +12.5% | +15.4% |